Dr Patricia Lynn Sutton, DO | |
425 Chester Pike, Norwood, PA 19074-1414 | |
(610) 532-0646 | |
(610) 532-1252 |
Full Name | Dr Patricia Lynn Sutton |
---|---|
Gender | Female |
Speciality | Family Medicine |
Location | 425 Chester Pike, Norwood, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144258138 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | OS-005269L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Patricia Lynn Sutton, DO 425 Chester Pike, P.o. Box 9, Norwood, PA 19074-1414 Ph: (610) 532-0646 | Dr Patricia Lynn Sutton, DO 425 Chester Pike, Norwood, PA 19074-1414 Ph: (610) 532-0646 |
News Archive
A Taiwanese research team led by Prof. Dar-Bin Shieh of Institute of Oral Medicine in Medical College at National Cheng Kung University has partnered with a research group led by Dr. Dennis Whitefield from National Research Council of Canada to develop innovative cancer diagnostic and treatment technologies.
Efforts to contain the spread of the Covid-19 pandemic are now the top priority of governments across the globe. As they make these life-saving decisions, it is particularly crucial for policymakers to accurately predict how the spread of the virus will change over time.
Work-related stress makes many of us lose sleep, and catching up on lost sleep is high on the agenda as the summer holidays approach. Poor sleep can't be turned into good overnight, but it pays off to try, as good sleeping habits keep us going on holiday and at work.
Researchers have discovered a new gene mutation they say causes Parkinson's disease. The mutation was identified in a large Swiss family with Parkinson's disease, using advanced DNA sequencing technology.
Y's Therapeutics, a privately held biopharmaceutical company, said today it has submitted applications to the Ethics Committee and Ministry of Health (BfArM) in Germany to begin Phase II clinical trials for its two most advanced projects, YSIL6 for rheumatoid arthritis and YSTH2 for asthma.
› Verified 2 days ago